PMID- 17226788
OWN - NLM
STAT- MEDLINE
DCOM- 20070404
LR  - 20181201
IS  - 0021-9541 (Print)
IS  - 0021-9541 (Linking)
VI  - 211
IP  - 1
DP  - 2007 Apr
TI  - From the laboratory bench to the patient's bedside: an update on clinical trials 
      with mesenchymal stem cells.
PG  - 27-35
AB  - Mesenchymal Stem Cells (MSCs) are non-hematopoietic multi-potent stem-like cells 
      that are capable of differentiating into both mesenchymal and non-mesenchymal 
      lineages. In fact, in addition to bone, cartilage, fat, and myoblasts, it has 
      been demonstrated that MSCs are capable of differentiating into neurons and 
      astrocytes in vitro and in vivo. MSCs are of interest because they are isolated 
      from a small aspirate of bone marrow and can be easily expanded in vitro. As 
      such, these cells are currently being tested for their potential use in cell and 
      gene therapy for a number of human diseases. Nevertheless, there are still some 
      open questions about origin, multipotentiality, and anatomical localization of 
      MSCs. In this review, we discuss clinical trials based on the use of MSCs in 
      cardiovascular diseases, such as treatment of acute myocardial infarction, 
      endstage ischemic heart disease, or prevention of vascular restenosis through 
      stem cell-mediated injury repair. We analyze data from clinical trials for 
      treatment of osteogenesis imperfecta (OI), which is a genetic disease 
      characterized by production of defective type I collagen. We describe progress 
      for neurological disease treatment with MSC transplants. We discuss data on 
      amyotrophic lateral sclerosis (ALS) and on lysosomal storage diseases (Hurler 
      syndrome and metachromatic leukodystrophy). A section of review is dedicated to 
      ongoing clinical trials, involving MSCs in treatment of steroid refractory Graft 
      Versus Host Disease (GVHD); periodontitis, which is a chronic disease affecting 
      periodontium and causing destruction of attachment apparatus, heart failure, and 
      bone fractures. Finally, we will provide information about biotech companies 
      developing MSC therapy.
CI  - (c) 2007 Wiley-Liss, Inc.
FAU - Giordano, Antonio
AU  - Giordano A
AD  - Sbarro Institute for Cancer Research and Molecular Medicine, Center for 
      Biotechnology, Temple University, Philadelphia, Pennsylvania, USA. 
      giordano@temple.edu
FAU - Galderisi, Umberto
AU  - Galderisi U
FAU - Marino, Ignazio R
AU  - Marino IR
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Cell Physiol
JT  - Journal of cellular physiology
JID - 0050222
SB  - IM
MH  - Bone Marrow Cells/cytology
MH  - *Cell- and Tissue-Based Therapy/trends
MH  - *Clinical Trials as Topic
MH  - Humans
MH  - *Mesenchymal Stem Cell Transplantation
MH  - Mesenchymal Stem Cells/*cytology
RF  - 71
EDAT- 2007/01/18 09:00
MHDA- 2007/04/05 09:00
CRDT- 2007/01/18 09:00
PHST- 2007/01/18 09:00 [pubmed]
PHST- 2007/04/05 09:00 [medline]
PHST- 2007/01/18 09:00 [entrez]
AID - 10.1002/jcp.20959 [doi]
PST - ppublish
SO  - J Cell Physiol. 2007 Apr;211(1):27-35. doi: 10.1002/jcp.20959.